First trimester aneuploidy screening in the presence of a vanishing twin: Implications for maternal serum markers

Prenatal Diagnosis

Volumn 30, Issue 3, 2010, Pages 235-240

  Spencer, K ^a   Staboulidou, I ^b   Nicolaides, K H ^b  

^a KING GEORGE HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Down syndrome; Free hCG; PAPP A; Prenatal screening; Trisomy; Vanishing twin

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PROTEIN;

ANEUPLOIDY; ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; PRIORITY JOURNAL; TRISOMY 21;

ABORTION, MISSED; ADULT; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DISEASES IN TWINS; FEMALE; FETAL DEATH; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC;

EID: 77349087527     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2445     Document Type: Article

References (44)

1. Abbas A, Sebire NJ, Johnson M, Bersinger N, Nicolaides KH. 1996. Maternal serum concentrations of pregnancy associated placental protein A and pregnancy specific B1 glycoprotein in multifetal pregnancies before and after fetal reduction. Hum Reprod 11: 900-902.
2. Bischof P, Amandruz M, Weil-Franck C, et al. 1984. The disappearance rate of pregnancy associated plasma protein A (PAPP-A) after the end of normal and abnormal pregnancies. Arch Gynecol 236: 93-98.
3. Chasen S, Perni SC, Predanic M, Kalish RB, Chervenak FA. 2006. Does a "vanishing twin" affect first trimester biochemistry in Down syndrome risk assessment? Am J Obstet Gynecol 195: 236-239.
4. Cowans NJ, Stamatopoulou A, Maiz N, Spencer K, Nicolaides KH. 2009. The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies. Prenat Diagn 29(6): 578-581.
5. Cuckle HS, Spencer K, Nicolaides KH. 2005. Down syndrome screening marker levels in women with a previous aneuploidy pregnancy. Prenat Diagn 25(1): 47-50.
6. De Sutter O, Bontinck J, Schutysers V, Van der Elst J, Gerris J, Dhout M. 2006. First trimester bleeding and pregnancy outcome in singletons after assisted reproduction. Hum Reprod 21: 1907-1911.
7. Dickey RP, Taylor SN, Lu PY, et al. 2002. Spontaneous reduction of multiple pregnancy: incidence and effect on outcome. Am J Obstet Gynecol 186: 77-83.
8. Gjerris AC, Loft A, Pinborg A, Christiansen M, Tabor A. 2009. The effect of a "vanishing twin" on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology. Hum Reprod 24: 55-62.
9. Jauniaux E, Elkazen N, Leroy F, Wilkin P, Rodesch F, Hustin J. 1988. Clinical and morphological aspects of the vanishing twin phenomenon. Obstet Gynecol 72: 577-581.
10. Johnson MR, Abbas A, Nicolaides KH. 1994. Maternal plasma levels of human chorionic gonadotrophin, oestradiol and progesterone in multifetal pregnancies before and after fetal reduction. J Endocrinol 143: 309-312.
11. Kagan KO, Frisova V, Nicolaides KH, Spencer K. 2007. Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6 weeks of gestation. Prenat Diagn 27: 849-853.
12. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. 2008. First trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 31: 493-502.
13. Korhonen J, Alfthan H, Ylostalo P, Veldhuis J, Stenman U-H. 1997. Disappearance of human chorionic gonadotropin and its α and β subunits after term pregnancy. Clin Chem 43: 2155-2163.
14. Landy HJ, Keith LG. 1998. The vanishing twin: a review. Hum Reprod Update 4: 177-183.
15. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. 2001. First trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 16: 1501-1504.
16. Lin TM, Halbert SP, Spellacy WN, Gall S. 1976. Human pregnancy associated plasma proteins during the post partum period. Am J Obstet Gynecol 124: 382-387.
17. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk orientated two stage screening. Ultrasound Obstet Gynecol 25: 221-226.
18. Robinson HP, Fleming JE. 1975. A critical evaluation of sonar "crown-rump length" measurements. Br J Obstet Gynaecol 82: 702-710.
19. Saidi MH. 1988. First trimester bleeding and the vanishing twin. A report of three cases. J Reprod Med 33: 831-834.
20. Smith R, Bischof P, Hughes G, Klopper A. 1979. Studies on pregnancy associated plasma protein A in the third trimester. Br J Obstet Gynaecol 86: 882-887.
21. Spencer K. 2000. Screening for trisomy 21 in twin pregnancies in the first trimester using free β-hCG and PAPP-A combined with fetal nuchal translucency thickness. Prenat Diagn 20: 91-95.
22. Spencer K. 2001. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 21(6): 445-447.
23. Spencer K. 2002. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited. Prenat Diagn 22(10): 874-876.
24. Spencer K 2005. Non invasive screening tests. In Multiple Pregnancy, Epidemiology, Gestation & Perinatal Outcome, Blickstein I, Keith LG (eds). Taylor & Francis: Abingdon; 368-384.
25. Spencer K, Nicolaides KH. 2003. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one stop clinic; a review of three years experience. BJOG 110: 276-280.
26. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta human chorionic gonadotopin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
27. Spencer K, Tul N, Nicolaides KH. 2000a. Maternal serum free betahCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 20(5): 390-394.
28. Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH. 2000b. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20(5): 411-416.
29. Spencer K, Ong CY, Liao AW, Nicolaides KH. 2000c. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 20: 491-494.
30. Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH. 2000d. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20(6): 495-499.
31. Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH. 2000e. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20(8): 673-675.
32. Spencer K, Ong CY, Liao AW, Nicolaides KH. 2000f. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. Prenat Diagn 20(10): 792-794.
33. Spencer K, Bindra R, Nicolaides KH. 2003. Maternal weight correction of maternal serum PAPP-A and free beta hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 23: 851-855.
34. Spencer K, Bindra R, Cacho AM, Nicolaides KH. 2004. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 24: 169-171.
35. Spencer K, Heath V, El-Sheikhah A, Ong CYT, Nicolaides KH. 2005a. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diag 25: 365-369.
36. Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. 2005b. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 25(10): 927-929.
37. Spencer K, Kagan KO, Nicolaides KH. 2008. Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 28: 49-52.
38. Spencer K, Staboulidou I, Cruz JDJ, Karagiannis G, Nicolaides KH. 2009a. Maternal serum screening marker levels in women with a previous aneuploidy pregnancy. Prenat Diagn 30: 1242-1243.
39. Spencer K, Spencer CE, Stamatopoulou A, Staboulidou I, Nicolaides KH. 2009b. Early vaginal bleeding has no impact on biochemical markers in first trimester aneuploidy screening. Prenat Diagn 29: in press.
40. Spencer K, Enofe O, Cowans NJ, Stamatopoulou A. 2009c. Is maternal renal disease a cause of elevated free beta hCG in first trimester aneuploidy screening? Prenat Diagn 29: 1045-1049.
41. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. 1999. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19(11): 1035-1042.
42. Wehmann RE, Nisula BC. 1979. Metabolic clearance rates of the subunits of human chorionic gonadotropin in man. J Clin Endocrinol Metab 48: 753-759.
43. Wehmann RE, Nisula BC. 1980. Renal clearance rates of the subunits of human chorionic gonadotropin in man. J Clin Endocrinol Metab 50: 674-679.
44. Wehmann RE, Nisula BC. 1981. Metabolic and clearance rates of purified human chorionic gonadotropin. J Clin Invest 68: 184-194.